Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Viatris Aims To Clear Up Investor ‘Disappointment’ After Breaking EBITDA Baseline

Company Also Reiterates $9bn Pre-Tax Proceeds Goal Via Divestments

Executive Summary

Days after Viatris announced a landmark new direction – the divestment of its global biosimilars plus other assets – and its full-year 2021 earnings, company management spoke with a leading investment bank to clarify issues raised by Viatris’ shareholders.

You may also be interested in...



Viatris Promises Clarity And Certainty On $9bn Transformation Plans

Confident that it will divest all non-core assets by the end of next year, Viatris says it understands “the importance of remaining engaged” with investors during the revamp. Meanwhile, the company is keeping a close eye on foreign exchange rate headwinds moving further into 2022, while electing not to row back further on its 2022 full-year guidance.

Generics Industry Braces For New Wave Of Price Pressure

With pricing pressures already creeping up in recent years, 2022 is set to see the generics industry caught in the middle as prices are further squeezed while costs continue to rise. As major players prepare to announce their first-quarter financial results, In Vivo looks at views from industry leaders on how these pressures are affecting their businesses, and how they can be expected to play out.

What’s Next? Five Things To Look Out For In May

This month, Eli Lilly’s Alimta blockbuster will lose patent protection in the US, while Teva – which will also publish its Q1 financial results – will see Bristol Myers Squibb begin its appeal process against a key UK ruling involving the originator’s Eliquis (apixaban) anticoagulant.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB151720

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel